Top

Published in:

01-02-2022 | Insulins | Original Article

Association between new markers of cardiovascular risk and hepatic insulin resistance in those at high risk of developing type 2 diabetes

Authors: Lucilla D. Monti, Camillo Bechi Genzano, Barbara Fontana, Elena Galluccio, Serena Spadoni, Andrea Magistro, Emanuele Bosi, Piermarco Piatti

Published in: Endocrine | Issue 2/2022

Abstract

Aim/hypothesis

Hepatic insulin resistance (HIR) is considered to be an independent predictor of metabolic disorders and plays an important role in systemic inflammation, which contributes to abnormalities in cardiovascular disease (CVD) risk factors. The aim of this study was to investigate the relationship between HIR and new markers of cardiovascular risks, including leptin/adiponectin ratio (L/A), lipoprotein(a) [Lp(a)], and tumor necrosis factor alpha (TNF-α), at comparable whole body insulin sensitivity in non-diabetic individuals with or without CVD and at high risk of developing type 2 diabetes.

Methods

The HIR index, L/A, Lp(a), and TNF-α were measured in 50 participants with CVD and in 200 without CVD (1:4 ratio). These were also matched for the homeostatic model assessment for insulin resistance (HOMA-IR) and Matsuda-insulin sensitivity index (ISI) in an observational study design.

Results

The HIR index (1.52 ± 0.14 vs. 1.45 ± 0.17, p < 0.02), L/A (3.22 ± 3.10 vs. 2.09 ± 2.27, p < 0.004), and levels of Lp(a) (66.6 ± 49.5 vs. 37.9 ± 3 6.8 mg/dL, p < 0.0001) and TNF-α (18.9 ± 21.8 vs. 5.4 ± 7.1 pg/mL, p < 0.0001) were higher in those with CVD than those without CVD. HOMA-IR and ISI were not significantly different (p = 0.88 and p = 0.35, respectively). The HIR index was directly correlated with L/A (r = 0.41, p < 0.0001), Lp(a) (r = 0.20, p < 0.002), TNF- α (r = 0.14, p < 0.03), and diastolic blood pressure (DBP) (r = 0.13, p < 0.03). The stepwise model analysis showed that L/A, Lp(a), and TNF-α explained about 20% of the variation in the HIR indices of all the participants (p < 0.02).

Conclusions/Interpretations

Our results suggest a positive association between HIR and new markers of cardiovascular risk [L/A, Lp(a), and TNF- α] at comparable whole body insulin sensitivity in those with or without CVD and at high risk of developing type 2 diabetes.

G. Reaven, Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb. Vasc. Biol. 32, 1754–9 (2012). https://doi.org/10.1161/ATVBAHA.111.241885CrossRefPubMed

K.B. Gast, N. Tjeerdema, T. Stijnen, J.W. Smit, O.M. Dekkers, Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS ONE 7, e52036 (2012). https://doi.org/10.1371/journal.pone.0052036CrossRefPubMedPubMedCentral

M. Stumvoll, S. Jacob, H.G. Wahl, B. Hauer, K. Loblein, P. Grauer, R. Becker, M. Nielsen, W. Renn, H. haring, Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in human. J. Clin. Endocrinol. Metab. 85, 3740–3745 (2000)PubMed

S. Zhao, C.M. Kusminski, P.E. Scherer, Adiponectin, leptin and cardiovascular disorders. Circ. Res 128, 136–149 (2021). https://doi.org/10.1161/CIRCRESAHACrossRefPubMedPubMedCentral

J. Zaletel, D.P. Barlovic, J. Prezelj, Adiponectin-leptin ratio: a useful estimate of insulin resistance in patients with Type 2 diabetes. J. Endocrinol. Invest 33, 514–8 (2010). https://doi.org/10.1007/BF03346639CrossRefPubMed

M. Inoue, M. Yano, M. Yamakado, Relationship between the adiponectin-leptin ratio and parameters of insulin resistance in subjects without hyperglycemia. Metabolism 55, 1248–54 (2006). https://doi.org/10.1016/j.metabol.2006.05.010CrossRefPubMed

P. Finneran, A. Pampana, S.A. Khetarpal, M. Trinder, A.P. Patel, K. Paruchuri, K. Aragam, G.M. Peloso, P. Natarajan, Lipoprotein (a) and coronary artery disease risk without a family history of heart disease. J. Am. Heart Assoc. 10, e017470 (2021). https://doi.org/10.1161/JAHA.120.017470CrossRefPubMedPubMedCentral

B.G. Nordestgaard, M.J. Chapman, K. Ray, J. Borén, F. Andreotti, G.F. Watts et al. European Atherosclerosis Society Consensus Panel. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur. Heart J. 31, 2844–53 (2010). https://doi.org/10.1093/eurheartj/ehq386CrossRefPubMedPubMedCentral

Emerging Risk Factors Collaboration, S. Erqou, S. Kaptoge, P.L. Perry, E. Di Angelantonio, A. Thompson, I.R. White et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302, 412–23 (2009). https://doi.org/10.1001/jama.2009.1063CrossRef

10.

R. Clarke, J.F. Peden, J.C. Hopewell, T. Kyriakou, A. Goel, S.C. Heath et al. PROCARDIS Consortium. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518–28 (2009). https://doi.org/10.1056/NEJMoa0902604CrossRefPubMed

11.

J.L. Jin, Y.X. Cao, H.W. Zhang, D. Sun, Q. Hua, Y.F. Li et al. Lipoprotein(a) and Cardiovascular Outcomes in Coronary Artery Disease in patients with prediabetes and diabetes. Diabetes Care 42, 1312–8 (2019). https://doi.org/10.2337/dc19-0274CrossRefPubMed

12.

R. Huang, S.-R. Zhao, Y. Li, F. Liu, Y. Gong, J. Xing, Z.-S. Xu, Association of tumor necrosis factor-α gene polymorphisms and coronary artery disease susceptibility: a systematic review and meta-analysis. BMC Med. Genet. 21, 29 (2020). https://doi.org/10.1186/s12881-020-0952-2CrossRefPubMedPubMedCentral

13.

D. Gupta, S. Varma, R.L. Khandelwal, Long-term effects of tumor necrosis factor-alpha treatment on insulin signaling pathway in HepG2 cells and HepG2 cells overexpressing constitutively active Akt/PKB. J. Cell Biochem 100, 593–607 (2007). https://doi.org/10.1002/jcb.21080CrossRefPubMed

14.

H. Zhao, X. Huang, J. Jiao, H. Zhang, J. Liu, W. Qin et al. Protein phosphatase 4 (PP4) functions as a critical regulator in tumor necrosis factor (TNF)-α-induced hepatic insulin resistance. Sci. Rep. 5, 18093 (2015). https://doi.org/10.1038/srep18093CrossRefPubMedPubMedCentral

15.

M.S.H. Akash, K. Rehman, A. Liaqat, Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J. Cell Biochem 119, 105–10 (2017). https://doi.org/10.1002/jcb.26174CrossRefPubMed

16.

K.G. Alberti, P. Zimmet, J. Shaw; IDF epidemiology task force consensus group, The metabolic syndrome–a new worldwide definition. Lancet 366, 1059–62 (2005). https://doi.org/10.1016/S0140-6736(05)67402-8CrossRefPubMed

17.

T.D. Topolski, J. LoGerfo, D.L. Patrick, B. Williams, J. Walwick, M.B. Patrick, The rapid assessment of physical activity (RAPA) among older adults. Prev. Chronic Dis. 3, 1–8 (2006)

18.

J. Vangipurapu, A. Stančáková, T. Kuulasmaa, J. Paananen, J. Kuusisto, E. Ferrannini et al. A novel surrogate index for hepatic insulin resistance. Diabetologia 54, 540–3 (2011). https://doi.org/10.1007/s00125-010-1966-7. & the EGIR-RISC Study GroupCrossRefPubMed

19.

R.A. DeFronzo, J.D. Tobin, R. Andres, Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214–E23 (1979). https://doi.org/10.1152/ajpendo.1979.237.3.E214CrossRefPubMed

20.

J. Vangipurapu, A. Stančáková, T. Kuulasmaa, P. Soininen, A.J. Kangas, M. Ala-Korpela, J. Kuusisto, M. Laakso, Association between liver insulin resistance and cardiovascular risk factors. J. Intern Med. 272, 402–408 (2012). https://doi.org/10.1111/j.1365-2796.2012.02540.xCrossRefPubMed

21.

D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–9 (1985). https://doi.org/10.1007/BF00280883CrossRef

22.

M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–70 (1999). https://doi.org/10.2337/diacare.22.9.1462CrossRefPubMed

23.

L.D. Monti, E. Setola, P.C. Lucotti, M.M. Marrocco-Trischitta, M. Comola, E. Galluccio, A. Poggi, S. Mammì, A.L. Catapano, G. Comi, R. Chiesa, E. Bosi, P.M. Piatti, Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 14, 893–900 (2012). https://doi.org/10.1111/j.1463-1326.2012.01615.xCrossRefPubMed

24.

E. Galluccio, P. Piatti, L. Citterio, P.C. Lucotti, E. Setola, L. Cassina et al. Hyperinsulinemia and impaired leptin-adiponectin ratio associate with endothelial nitric oxide synthase polymorphisms in subjects with in-stent restenosis. Am. J. Physiol. Endocrinol. Metab. 294, E978–E86 (2008). https://doi.org/10.1152/ajpendo.00003.2008CrossRefPubMed

25.

P. Piatti, C. Di Mario, L.D. Monti, G. Fragasso, F. Sgura, A. Caumo et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108, 2074–81 (2003). https://doi.org/10.1161/01.CIR.0000095272.67948.17CrossRefPubMed

26.

M. Matsuda, I. Shimomura, Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Rev. Endocr. Metab. Disord. 15, 1–10 (2014). https://doi.org/10.1007/s11154-013-9271-7CrossRefPubMed

27.

Y. Li, L. Ding, W. Hassan, D. Abdelkader, J. Shang, Adipokines and hepatic insulin resistance. J. Diabetes Res 2013, 170532 (2013). https://doi.org/10.1155/2013/170532CrossRefPubMedPubMedCentral

28.

A. Baranova, S.I. Gowder, K. Schlauch, H. Elariny, R. Collantes, A. Afendy, J.P. Ong, Z. Goodman, V. Chandhoke, Z.M. Younossi, Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes. Surg. 16, 1118–1125 (2006). https://doi.org/10.1381/096089206778392149CrossRefPubMed

29.

N. Vrachnis, P. Belitsos, S. Sifakis, K. Dafopoulos, C. Siristatidis, K.I. Pappa, Z. Iliodromiti, Role of adipokines and other inflammatory mediators in gestational diabetes mellitus and previous gestational diabetes mellitus. Int J. Endocrinol. 2012, 549748 (2012). https://doi.org/10.1155/2012/549748CrossRefPubMedPubMedCentral

30.

A. Gastaldelli, S.A. Harrison, R. Belfort-Aguilar, L.J. Hardies, B. Balas, S. Schenker, K. Cusi, Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50, 1087–93 (2009). https://doi.org/10.1002/hep.23116CrossRefPubMed

31.

H. Oku, F. Matsuura, M. Koseki, J.C. Sandoval, M. Yuasa-Kawase, K. Tsubakio-Yamamoto, D. Masuda, N. Maeda, T. Ohama, M. Ishigami, M. Nishida, K. Hirano, S. Kihara, M. Hori, I. Shimomura, S. Yamashita, Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. Febs. Lett. 581, 5029–5033 (2007). https://doi.org/10.1016/j.bbrc.2008.08.009CrossRefPubMed

32.

F. Matsuura, H. Oku, M. Koseki, J.C. Sandoval, M. Yuasa-Kawase, K. Tsubakio-Yamamoto, D. Masuda, N. Maeda, K. Tsujii, M. Ishigami, M. Nishida, K. Hirano, S. Kihara, M. Hori, I. Shimomura, S. Yamashita, Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem. Biophys. Res. Commun. 358, 1091–1095 (2007). https://doi.org/10.1016/j.bbrc.2007.05.040CrossRefPubMed

33.

D.L. Rainwater, S.M. Haffner, Insulin and 2-hour glucose levels are inversely related to Lp (a) concentrations controlled for LPA genotype. Arterioscler Thromb. Vasc. Biol. 18, 1335–1341 (1998). https://doi.org/10.1161/01.atv.18.8.1335CrossRefPubMed

34.

S.M. Haffner, P. Karhapaa, D.L. Rainwater, L. Mykkanen, G. Aldrete Jr, M. Laakso, Insulin sensitivity and Lp (a) concentrations in normoglycemic men. Diabetes Care 18, 193–189 (1995). https://doi.org/10.2337/diacare.18.2.193CrossRefPubMed

35.

H. Vaverková, D. Karásek, M. Halenka, L. Cibíčková, V. Kubíčková, Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects. Physiol. Res 66, S113–S120 (2017). https://doi.org/10.33549/physiolres.933583.CrossRefPubMed

36.

G. Ferretti, T. Bacchetti, T.P. Johnston, M. Banach, M. Pirro, A. Sahebkar, Lipoprotein(a): a missing culprit in the management of athero-thrombosis? J. Cell Physiol. 233(4), 2966–81 (2018). https://doi.org/10.1002/jcp.26050CrossRefPubMed

37.

J.P. Fisher, C.N. Young, P.J. Fadel, Central sympathetic overactivity: maladies and mechanisms. Auton. Neurosci. 148(1-2), 5–15 (2009). https://doi.org/10.1016/j.autneu.2009.02.003CrossRefPubMedPubMedCentral

38.

Lautt WW. Hepatic Circulation: Physiology and Pathophysiology. San Rafael (CA): Morgan & Claypool Life Sciences. 2009. Colloquium Series on Integrated Systems Physiology: From Molecule to Function to Disease. https://doi.org/10.4199/C00004ED1V01Y200910ISP001

39.

R.A. Rizza, E. Cryer, Haymond, J.E. Gerich, Adrenergic mechanisms for effects of epinephrine on glucose production and clearance in man. J. Clin. Invest 65, 682–689 (1980). https://doi.org/10.1172/JCI109714CrossRefPubMedPubMedCentral

40.

T.K.T. Lam, H. Yoshii, C.A. Haber, E. Bogdanovic, L. Lam, I.G. Fantus, A. Giacca, Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am. J. Physiol. 283, E682–E691 (2002). https://doi.org/10.1152/ajpendo.00038.2002CrossRef

41.

L. Li, G.-Y. Yang, Effect of hepatic glucose production on acute insulin resistance induced by lipid-infusion in awake rats. World J. Gastroenterol. 10, 3208–3211 (2004). https://doi.org/10.3748/wjg.v10.i21.3208CrossRefPubMedPubMedCentral

42.

E.W. Kraegen, G.J. Cooney, J. Ye, A.L. Thompson, Triglycerides, fatty acids and insulin resistance—hyperinsulinemia. Exp. Clin. Endocrinol. Diabetes 109, S516–26 (2001). https://doi.org/10.1055/s-2001-15114CrossRefPubMed

Title: Association between new markers of cardiovascular risk and hepatic insulin resistance in those at high risk of developing type 2 diabetes
Authors: Lucilla D. Monti
Camillo Bechi Genzano
Barbara Fontana
Elena Galluccio
Serena Spadoni
Andrea Magistro
Emanuele Bosi
Piermarco Piatti
Publication date: 01-02-2022
Publisher: Springer US
Keywords: Insulins
Insulins
Type 2 Diabetes
Published in: Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02868-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association between new markers of cardiovascular risk and hepatic insulin resistance in those at high risk of developing type 2 diabetes

Abstract

Aim/hypothesis

Methods

Results

Conclusions/Interpretations

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aim/hypothesis

Methods

Results

Conclusions/Interpretations

Please log in to get access to this content

Other articles of this Issue 2/2022

Machine learning-based clinical outcome prediction in surgery for acromegaly

Correction: Hypercalcemia during pregnancy: management and outcomes for mother and child

Quantitative T1 mapping MRI for the assessment of extraocular muscle fibrosis in thyroid-associated ophthalmopathy

Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors

Spontaneous extracapsular parathyroid adenoma hemorrhage: when surgery is required?

Regenerative approaches to preserve pancreatic β-cell mass and function in diabetes pathogenesis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page